KBC Group NV Has $246,000 Holdings in Hims & Hers Health, Inc. $HIMS

KBC Group NV trimmed its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 41.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,941 shares of the company’s stock after selling 3,487 shares during the quarter. KBC Group NV’s holdings in Hims & Hers Health were worth $246,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of HIMS. Quaker Wealth Management LLC bought a new stake in shares of Hims & Hers Health during the 2nd quarter worth about $29,000. Bessemer Group Inc. raised its stake in shares of Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after acquiring an additional 312 shares in the last quarter. Geneos Wealth Management Inc. acquired a new stake in Hims & Hers Health in the 1st quarter worth approximately $30,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Hims & Hers Health during the first quarter worth approximately $41,000. Finally, Larson Financial Group LLC grew its holdings in Hims & Hers Health by 47.7% during the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock valued at $42,000 after purchasing an additional 458 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $36.36 on Wednesday. The company’s fifty day moving average is $50.12 and its two-hundred day moving average is $51.42. Hims & Hers Health, Inc. has a 52-week low of $20.02 and a 52-week high of $72.98. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The firm has a market capitalization of $8.28 billion, a price-to-earnings ratio of 67.33, a P/E/G ratio of 7.08 and a beta of 2.20.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The company had revenue of $598.98 million during the quarter, compared to the consensus estimate of $578.99 million. During the same quarter in the previous year, the business posted $0.32 EPS. The firm’s quarterly revenue was up 49.2% on a year-over-year basis. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health announced that its Board of Directors has authorized a stock repurchase plan on Monday, November 17th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 3% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its shares are undervalued.

Insiders Place Their Bets

In related news, CFO Oluyemi Okupe sold 11,592 shares of the firm’s stock in a transaction on Friday, October 17th. The stock was sold at an average price of $57.13, for a total value of $662,250.96. Following the completion of the transaction, the chief financial officer directly owned 70,232 shares of the company’s stock, valued at $4,012,354.16. This trade represents a 14.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael Chi sold 900 shares of Hims & Hers Health stock in a transaction on Friday, October 10th. The stock was sold at an average price of $58.25, for a total transaction of $52,425.00. Following the sale, the insider owned 291,439 shares in the company, valued at $16,976,321.75. This represents a 0.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 584,209 shares of company stock worth $31,837,916. 17.71% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of analyst reports. Bank of America boosted their price objective on shares of Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a research note on Tuesday, November 4th. KeyCorp initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, October 21st. They set a “sector weight” rating for the company. Truist Financial decreased their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a report on Monday, August 18th. Canaccord Genuity Group reiterated a “buy” rating and issued a $68.00 price objective on shares of Hims & Hers Health in a research note on Friday, September 12th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Two investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, Hims & Hers Health has an average rating of “Reduce” and a consensus target price of $45.27.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.